Osmers R G, Rybicki T, Meden H, Kuhn W
Department of Obstetrics and Gynecology, University of Göttingen, Germany.
Eur J Gynaecol Oncol. 1997;18(3):177-82.
In a retrospective study, a total of 120 ovarian cancer patients were paired in terms of staging, grading, patent age, and operative and cytostatic therapy. Half of the patients underwent radioimmunoscintigraphy for diagnostic purposes. From the point of view of possible adjuvant immunological therapy, we investigated to what extent patients with treated ovarian cancer benefit from the application of OC 125 in terms of survival time. In our study we have been able to show that at favorable stages (FIGO II) the patient benefitted more from a radioimmunoscintigraphy than at prognostically unfavorable stages (FIGO IV). Even within FIGO stage III we have been able to show, thanks to the large number of cases, that patients with an NED situation benefitted significantly more form radioimmunoscintigraphy in terms of survival than those with residual tumors. Throughout FIGO stage III, patients with radioimmunoscintigraphy showed significantly superior 5-year survival rates (p < 0.05) than those without radioimmunoscintigraphy. These data would appear to justify prospective studies to establish to what extent ovarian cancer patients benefit from an adjuvant application of OC 125 in terms of the 5-years survival rate and the relapse-free interval.
在一项回顾性研究中，根据分期、分级、患者年龄以及手术和细胞抑制治疗情况，总共对120例卵巢癌患者进行了配对。其中一半患者接受放射免疫闪烁扫描以用于诊断目的。从可能的辅助免疫治疗角度出发，我们研究了接受治疗的卵巢癌患者在生存时间方面从应用OC 125中获益的程度。在我们的研究中，我们能够表明，在有利分期（国际妇产科联盟（FIGO）II期），患者从放射免疫闪烁扫描中获益比在预后不利分期（FIGO IV期）更多。即使在FIGO III期，由于病例数量众多，我们也能够表明，处于无疾病证据（NED）状态的患者在生存方面从放射免疫闪烁扫描中获益明显多于有残留肿瘤的患者。在整个FIGO III期，接受放射免疫闪烁扫描的患者5年生存率显著高于未接受放射免疫闪烁扫描的患者（p < 0.05）。这些数据似乎证明有必要进行前瞻性研究，以确定卵巢癌患者在5年生存率和无复发生存期方面从辅助应用OC 125中获益的程度。
